United Therapeutics Inc. (NASDAQ:UTHR) stock gained on Monday after it shared positive news regarding its drug ralinepag, which achieved a significant milestone in clinical trials.

The stock’s movement comes as broader markets experienced declines, with the Nasdaq down 1.40% on the previous trading day.

Lung/Heart Disease Data

The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint, demonstrating a 55% reduction in the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH).

PAH is characterized by high blood pressure in the lung arteries, caused by narrowing and remodeling of the vessels, which forces the right heart to work harder, leading to heart failure.

Additionally, the study showed that ralinepag increased the odds of clinical improvement by 47% in predominantly pre-treated patients, with the company planning to submit a New Drug Application (NDA) to the FDA by ...